Answers are grounded in this paper and cite their sources.
Article1 July 1968Serology of Human CryptococcosisDARRYL D. BINDSCHADLER, M.D., JOHN E. BENNETT, M.D., F.A.C.P.DARRYL D. BINDSCHADLER, M.D., JOHN E. BENNETT, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-69-1-45 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSixty-nine patients with cryptococcal meningoencephalitis and six patients with nonmeningeal cryptococcosis were studied serologically. Twenty-nine of the 75 patients had serum anticryptococcal antibody by an indirect fluorescence test (IFA). Titers ranged from 1:1 to 1:32. Forty-seven patients had cryptococcal antigen in serum or cerebrospinal fluid (CSF) detected by a complement fixation (CF) test. Of the 47, 7 also had serum antibody. Antigen titers ranged from 1:1 to 1:2048 in CSF and from 1:4 to 1:512 in serum. Only six patients, four with cryptococcal meningoencephalitis, were negative to both serologic tests.Among the patients with cryptococcal meningoencephalitis, those with Cryptococcus in india ink smears of CSF usually had cryptococcal antigen in blood, CSF, or both. Patients with negative india ink smears despite positive CSF cultures tended to have serum anticryptococcal antibody. The patients with anticryptococcal antibody were generally less ill than those with antigen and obtained a better response to therapy with amphotericin B.Although the CF test for antigen has been specific for cryptococcosis, a few false-positive tests for antibody were found. Among 253 control sera, 1.6% were IFA positive, as were sera from 6% of blastomycosis patients and from 12% of histoplasmosis patients. A cryptococcal skin test was also noted to produce false-positive IFA reactions in 31% of 48 patients and could create errors in serologic diagnosis.The two serologic tests used together have sufficient specificity and sensitivity to be a useful aid in the rapid diagnosis of cryptococcosis....References1. KAUFMAN L: Serology of systemic fungus diseases. Public Health Rep. 81: 177, 1966. CrossrefMedlineGoogle Scholar2. KIMBALLHASENCLEVERWOLFF HRHFSM: Detection of circulating antibody in human cryptococcosis by means of a bentonite flocculation technique. Amer. Rev. Resp. Dis. 95: 631, 1967. MedlineGoogle Scholar3. GORDONVEDDER MADK: Serologic tests in diagnosis and prognosis of cryptococcosis. JAMA 197: 961, 1966. CrossrefMedlineGoogle Scholar4. ATKINSONBENNETT AJJE: Experience with a new skin test antigen from Cryptococcus neoformans. Amer. Rev. Resp. Dis. 97: 637, 1968. MedlineGoogle Scholar5. WILSONBENNETTBAILEY DEJEJW: Serologic grouping of Cryptococcus neoformans. Proc. Soc. Exp. Biol. Med. In press. Google Scholar6. BENNETTHASENCLEVER JEHF: Cryptococcus neoformans polysaccharide: studies of serologic properties and role in infection. J. Immun. 94: 916, 1965. MedlineGoogle Scholar7. BENNETTHASENCLEVERTYNES JEHFBS: Detection of cryptococcal polysaccharide in serum and spinal fluid: value in diagnosis and prognosis. Trans. Ass. Amer. Physicians 77: 145, 1964. MedlineGoogle Scholar8. VOGEL RA: The indirect fluorescent antibody test for the detection of antibody in human cryptococcal disease. J. Infect. Dis. 116: 573, 1966. CrossrefMedlineGoogle Scholar9. POLLOCKWARD AQLM: A hemagglutination test for cryptococcosis. Amer. J. Med. 32: 6, 1962. CrossrefMedlineGoogle Scholar10. CAMPBELLHILL CCGB: Further studies on the development of complement-fixing antibodies and precipitins in healthy histoplasmin-sensitive persons following a single histoplasmin skin test. Amer. Rev. Resp. Dis. 90: 927, 1964. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Bethesda, MarylandFrom the National Institute of Allergy and Infectious Diseases, Laboratory of Clinical Investigations, Infectious Disease Section, National Institutes of Health, Bethesda, Md.Requests for reprints should be addressed to John E. Bennett, M.D., Clinical Center, Room 11N-210, National Institutes of Health, Bethesda, Md. 20014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByImmunotherapy against Systemic Fungal Infections Based on Monoclonal AntibodiesCryptococcosisCryptococcosisDiagnosis and Laboratory TechniquesTherapy of CryptococcosisPneumocystis and Other Less Common Fungal InfectionsCryptococcosis: From Discovering the Natural Reservoir of its Etiology to the Genetic Manipulation of Cryptococcus neoformans: Milestones in Cryptococcal Research by Intramural Investigators at NIAIDDiagnosis of CryptococcosisCryptococcosisPneumocystis and Other Less Common Fungal InfectionsAntibody Response to Cryptococcus neoformans Proteins in Rodents and HumansCryptococcal Pneumonia Complicating PregnancyA latex cryptococcal antigen agglutination test for diagnosis and monitoring of therapy for cryptococcosisSerum antibody response to active infection with Cryptococcus neoformans and its varieties in immunocompetent subjectsCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformansAntibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individualsElimination of false-positive serum reactivity in latex agglutination test for cryptococcal antigen in human immunodeficiency virus-infected populationEvaluation of new monoclonal antibody-based latex agglutination test for detection of cryptococcal polysaccharide antigen in serum and cerebrospinal fluidCryptococcosisCryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicityCryptococcosisGenetic control of the humoral response to cryptococcal capsular polysaccharide in miceProduction, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharideProtection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibodyCryptococcal meningoencephalitis: intrathecal immunological responseEvaluation of cross-reactions in Histoplasma capsulatum serologic testsCryptococcal Disease in Patients with the Acquired Immunodeficiency Syndrome Diagnostic Features and Outcome of TreatmentABIGAIL ZUGER, M.D., EDDIE LOUIE, M.D., ROBERT S. HOLZMAN, M.D., MICHAEL S. SIMBERKOFF, M.D., JAMES J. RAHAL, M.D.Tierexperimentelle cryptococcose des auges unter dem einfluß einer passageren niereninsuffizienz — Eine pathohistologische studie —Cryptococcal Infection of the Central Nervous SystemNon-specific immunosuppression by Cryptococcus neoformans infectionFungal Infections in the Immunocompromised HostImmunity to Fungal InfectionsExperimental cryptococcosis in guinea pigsImmunosuppression by avirulent, pseudohyphal forms ofCryptococcus neoformansIn vitro interactions of immune lymphocytes and Cryptococcus neoformansImmunodiagnosis Detection of Antigens in Body FluidsImmunosuppression by avirulent, pseudohyphal forms ofCryptococcus neoformansImmunology of Invasive Fungal InfectionsPassive immunization in murine cryptococcosisOpportunistic Infections of the LungCryptococcosis in the United Kingdom and the Irish Republic: an analysis of 69 casesExperimental cryptococcal myocarditisCryptococcosis in the Light of Three CasesOpportunistic pneumoniasExperimental cryptococcosis in normal and B-cell-deficient miceHost defense in cryptococcosis. III. In vivo alteration of immunityCryptococcose neuro-méningée. Considérations diagnostiques et thérapeutiques (A propos de 5 observations personnelles et d'une revue de la littérature)Host defense in cryptococcosisHypersensitivity pneumonitis with antibodies to Cryptococcus neoformansKomplikationen und supportive Therapie der Leukämien und malignen Non-Hodgkin-LymphomeImmunité humorale dans la cryptococcoseEffects of stimulation and suppression of cell-mediated immunity on experimental cryptococcosisCommercial Test Sensitivity to Cryptococcal AntigenCARL B. LAUTER, M.D., F.A.C.P.Characterization of immunoglobulin classes of human antibodies to cryptococcus neoformansNature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformansLatex agglutination in the diagnosis of pneumococcal infectionOpportunistic Invasive Fungal Infections in Patients with Leukaemia and LymphomaPossibility of diagnosing meningitis by gas chromatography: cryptococcal meningitisAbnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infectionAntibodies to Epstein-Barr virus in patients with cryptococcosisSeptic arthritis due to nonencapsulated cryptococcus neoformans with coexisting sarcoidosisCell-mediated immunity in cryptococcosisDiagnosis and Treatment of Systemic MycosesPrognostic Factors in Cryptococcal Meningitis A Study in 111 CasesRICHARD D. DIAMOND, M.D., JOHN E. BENNETT, M.D., F.A.C.P.Antibody-dependent Killing of Cryptococcus neoformans by Human Peripheral Blood Mononuclear CellsTorulomas (cryptococcal granulomata) of the central nervous systemCryptococcosis: Two Cases in Military Hospitals in BritainDiagnosis of Cryptococcal MeningitisDiagnosis of Cryptococcal Uveitis with Hypertonic MediaCryptococcosisPulmonary Cryptococcosis:L-DOPA FOR PROGRESSIVE SUPRANUCLEAR PALSYWHEN IS THE CRYPTOCOCCUS DANGEROUS?CELESTIAL PATHOLOGYImmunologie der Kryptokokkose*Variant Forms of Pulmonary CryptococcosisBAYARD TYNES, M.D., F.A.C.P., KATHLEEN N. MASON, M.S., ANNE E. JENNINGS, JOHN E. BENNETT, M.D., F.A.C.P. 1 July 1968Volume 69, Issue 1Page: 45-52KeywordsAntigensColony stimulating factorCryptococcosisInfectious diseasesMeningoencephalitisPatientsResearch laboratoriesSerologySkin testsSpecificity Issue Published: 1 July 1968 PDF DownloadLoading ...
No takes yet. Share an insight, caveat, or question.
DARRYL D. BINDSCHADLER (1968) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: